Late presentation of human T-lymphotropic virus type 1 infection in Spain reflects suboptimal testing strategies.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 04 05 2022
revised: 10 06 2022
accepted: 18 07 2022
pubmed: 29 7 2022
medline: 9 9 2022
entrez: 28 7 2022
Statut: ppublish

Résumé

Although only 10% of persons infected with human T-lymphotropic virus type 1 (HTLV-1) may develop virus-associated illnesses over their lifetime, missing the earlier diagnosis of asymptomatic carriers frequently leads to late presentation. A nationwide HTLV-1 register was created in Spain in 1989. We examined the main demographics and clinical features at the time of the first diagnosis for more than three decades. A total of 428 individuals infected with HTLV-1 had been reported in Spain until the end of 2021. Up to 96 (22%) individuals presented clinically with HTLV-1-associated conditions, including subacute myelopathy (57%), T-cell lymphoma (34%), or Strongyloides stercoralis infestation (8%). Since 2008, HTLV-1 diagnosis has been made at blood banks (44%) or clinics (56%). Native Spaniards and Sub-Saharan Africans are overrepresented among patients presenting with HTLV-1-associated illnesses suggesting that poor epidemiological and/or clinical suspicion, which led to the late presentation are more frequent in them than carriers from Latin America (LATAM) (31.7% vs 20.4%, respectively; P = 0.015). HTLV-1 infection in Spain is frequently diagnosed in patients presenting with characteristic illnesses. Although screening in blood banks mostly identifies asymptomatic carriers from LATAM, a disproportionately high number of Spaniards and Africans are diagnosed too late at the time of clinical manifestations. Expanding testing to all pregnant women and clinics for sexually transmitted infections could help to unveil HTLV-1 asymptomatic carriers.

Identifiants

pubmed: 35902023
pii: S1201-9712(22)00440-4
doi: 10.1016/j.ijid.2022.07.043
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

970-975

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of competing interest The authors have no competing interests to declare.

Auteurs

Carmen de Mendoza (C)

Internal Medicine Laboratory, Puerta de Hierro University Hospital & Research Foundation-IDIPHISA, Madrid, Spain. Electronic address: cmendoza.cdm@gmail.com.

Leire Pérez (L)

Internal Medicine Department, Gregorio Marañón University Hospital, Madrid, Spain.

Mario Fernández-Ruiz (M)

Infectious Diseases Unit, 12 Octubre University Hospital, Madrid, Spain.

María José Pena (MJ)

Microbiology Department, Doctor Negrín University Hospital, Las Palmas de Gran Canaria, Spain.

José Manuel Ramos (JM)

Infectious Diseases Unit, Alicante General University Hospital, Alicante, Spain.

Alberto Richart (A)

Regional Transfusion Center, Madrid, Spain.

María Piron (M)

Catalan Tissue & Blood Bank, Barcelona, Spain.

Ariadna Rando (A)

Microbiology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

Elisenda Miró (E)

Microbiology Department, Santa Creu i Sant Pau University Hospital, Barcelona, Spain.

Gabriel Reina (G)

Microbiology Department, Clínica Universidad de Navarra, Pamplona, Spain.

Beatriz Encinas (B)

Internal Medicine Laboratory, Puerta de Hierro University Hospital & Research Foundation-IDIPHISA, Madrid, Spain.

Silvia Rojo (S)

Microbiology Department, Hospital Clínico Universitario, Valladolid, Spain.

Antonio Manuel Rodriguez-Iglesias (AM)

Microbiology Department, University of Cadiz, Cadiz, Spain.

Rafael Benito (R)

Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.

Antonio Aguilera (A)

Microbiology Department, University of Santiago, Santiago de Compostela, Spain.

Ana Treviño (A)

UNIR Health Sciences School & Medical Center, Madrid, Spain.

Octavio Corral (O)

UNIR Health Sciences School & Medical Center, Madrid, Spain.

Vicente Soriano (V)

UNIR Health Sciences School & Medical Center, Madrid, Spain. Electronic address: vicente.soriano@unir.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH